Hepatitis E virus (HEV) infection is known to run a self-limiting course. Sporadic cases of acute hepatitis due to infection with HEV genotype 3, present in pig populations, are increasingly recognized. Zoonotic transmission seems infrequent. The entity of unexplained chronic hepatitis after liver t
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients
โ Scribed by Sven Pischke; Pothakamuri V. Suneetha; Christine Baechlein; Hannelore Barg-Hock; Albert Heim; Nassim Kamar; Jerome Schlue; Christian P. Strassburg; Frank Lehner; Regina Raupach; Birgit Bremer; Peter Magerstedt; Markus Cornberg; Frauke Seehusen; Wolfgang Baumgaertner; Juergen Klempnauer; Jacques Izopet; Michael P. Manns; B. Grummer; Heiner Wedemeyer
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 256 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21958
No coin nor oath required. For personal study only.
โฆ Synopsis
Hepatitis E virus (HEV) infection induces self-limiting liver disease in immunocompetent individuals. Cases of chronic hepatitis E have recently been identified in organ transplant recipients. We questioned if chronic hepatitis E plays a role in graft hepatitis after liver transplantation in a low endemic area. Two hundred twenty-six liver transplant recipients, 129 nontransplanted patients with chronic liver disease, and 108 healthy controls were tested for HEV antibodies. HEV RNA was investigated in all sera from transplanted patients. HEV antibodies were detected in 1 healthy control (1%), 4 patients with chronic liver disease (3%), and 10 liver transplant recipients (4%). Three liver transplant patients also tested positive for HEV RNA. Two of them developed persistent viremia with HEV genotype 3. The patients were anti-HEV immunoglobulin G-negative and HEV RNA-negative before transplantation and had an episode of acute hepatitis 5 or 7 months after transplantation, which led to advanced liver fibrosis after 22 months in 1 patient. Seroconversion to anti-HEV occurred not before 4 months after the first detection of HEV RNA. The possibility of reverse zoonotic transmission was experimentally confirmed by the infection of 5 pigs with a patient's serum. The pigs showed histological inflammation in the liver, and HEV RNA was detectable in different organs, including muscle. In conclusion, the prevalence of HEV infection in Central European liver transplant recipients is low; however, chronic hepatitis E may occur and needs to be considered in the differential diagnosis of graft hepatitis. The diagnosis of HEV infection should be based on HEV RNA determination in immunosuppressed patients. We suggest that immunocompromised individuals should avoid eating uncooked meat and contact with possibly HEV-infected animals.
๐ SIMILAR VOLUMES
Hepatitis E virus (HEV) infection is known to run a self-limited course. Recently, chronic hepatitis E has been described in several immunosuppressed patients after solid organ transplantation. The prevalence of HEV infection after transplantation, however, is unknown. We studied HEV parameters [HEV
To determine the safety and efficacy of ganciclovir usually experience progressive liver disease over an treatment of hepatitis B virus (HBV) infection after liver accelerated time course and pose a difficult managetransplantation, nine patients (seven males, two females; ment challenge. The treatm
Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United Sta
The clinical significance of HGV infection is uncertain. ## Although hepatitis G virus infection (HGV) is usually Hepatitis G viremia has been documented in patients with asymptomatic, it has been associated with mild hepatic injury. acute hepatitis 1,6,7 and can persist for years, 1,5-7 althoug
Hepatitis C recurrence after liver transplantation is a serious problem, leading to increased graft loss and morbidity in some individuals. Treatment with interferon and other agents is controversial and not highly efficacious. The use of an effective antiviral agent to reduce or eliminate viral bur